Skip to main content
Clinical Trials/NCT00567801
NCT00567801
Terminated
Phase 3

Prospektive, Randomisierte Multicenter-Studie Zur Optimierung Der Therapie Der Akuten Ischämie Der Unteren Extremitäten Durch Die Kontrollierte Extremitätenreperfusion (Prospective, Randomized Multicenter - Study for Optimization of Therapy of the Acute Ischemic Limb by Controlled Reperfusion)

University Hospital Freiburg23 sites in 2 countries250 target enrollmentSeptember 2002

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Lower Extremity Ischemia
Sponsor
University Hospital Freiburg
Enrollment
250
Locations
23
Primary Endpoint
Amputation-free survival
Status
Terminated
Last Updated
17 years ago

Overview

Brief Summary

The purpose of this study is to prove the findings of a preliminary study which strongly suggest the hypothesis that the result of conventional embolectomy for acute, severe lower-limb ischemia can be improved by controlled reperfusion.

Registry
clinicaltrials.gov
Start Date
September 2002
End Date
September 2010
Last Updated
17 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
University Hospital Freiburg

Eligibility Criteria

Inclusion Criteria

  • Patients aged 18 years or older
  • Patients with arterial occlusion of one or both lower limbs with acute decompensated ischemia (Rutherford IIA to III)
  • Informed consent of the patient

Exclusion Criteria

  • Previous attempt of recanalisation (e.g. lysis therapy)
  • Known A. poplitea aneurysm of the affected extremity
  • Severe heart failure NYHA IV
  • Known atrial thrombus
  • Terminal renal insufficiency (creatinine \>10mg/dl or current dialysis therapy, previous transplantation of kidney)
  • Hypersensitivity to allopurinol
  • Hypersensitivity to one component part of the reperfusion solution
  • Participation in a clinical trial during the study or 30 days before
  • Pregnancy or lactation
  • Patient incapable of contracting or not able to understand the character, meaning and consequences of the clinical trial

Outcomes

Primary Outcomes

Amputation-free survival

Time Frame: 28 days

Secondary Outcomes

  • Systemic complications in both therapy groups(4 weeks)
  • Tolerance of reperfusion solution(4 weeks)
  • Neurological status (motor function, sensor function) of ischemic limb(4 weeks)
  • Lethality(12 months)

Study Sites (23)

Loading locations...

Similar Trials